Effect of chronic ritonavir administration on pregnant rats and their fetuses.
In view of the very important role played by ritonavir in the prevention of maternal-fetal HIV-vertical transmission, the aim of this experimental study was to evaluate its possible effects on several important obstetric parameters. Ritonavir was administered daily to three groups of pregnant rats (E1 = 20 mg/kg; E2 = 60 mg/kg; E3 = 180 mg/kg; n = 10 in every group) from 'zero' up to the 20th day of pregnancy. Controls (n = 10) were injected with the drug vehicle (propyleneglycol) in the same schedule. We evaluated the effects on fetal and maternal weight gain, placental weight, number of implantations and resorptions, malformations, fertility rate, and maternal and fetal death rates. Body weight gain of the E3 group was significantly lower than that of the other groups, most likely due to a toxic effect of the highest dose of ritonavir. Ritonavir did not affect the number of implantations. Group E3 had five resorptions and some reduction in fertility. The mortality rate was significantly affected by ritonavir (2/10 maternal deaths in E2 and 4/10 in E3). On the other hand, no alterations were observed in the fetuses, a finding which could be due at least in part to the protective action of placental P-glycoprotein.
Carvalho
A M
AM
University of José do Rosário Vellano School of Medicine, Alfenas (MG), (Brazil).
Oliveira-Filho
R M
RM
Simões
M J
MJ
Amed
A A
AA
Kulay
L
L
D000818:Animals; D005260:Female; D005327:Fetal Resorption / Q000139:chemically induced; D017320:HIV Protease Inhibitors / Q000633:toxicity*; D007247:Infertility, Female / Q000139:chemically induced; D011247:Pregnancy; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D019438:Ritonavir / Q000633:toxicity*; D015430:Weight Gain
D017320:HIV Protease Inhibitors; D019438:Ritonavir